Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

72.20 +2.19 (+3.12%)

Streaming Delayed Price Updated: 3:27 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

August 12, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

July 18, 2024

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗

July 14, 2024

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Via Benzinga

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗

July 11, 2024

Via Benzinga

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 28, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 23, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 15, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 ↗

May 13, 2024

APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 13, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Earnings Superstars: 3 Stocks Primed to Outperform This Quarter ↗

May 08, 2024

Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors.

Via InvestorPlace

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

May 06, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

March 25, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2024

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

March 12, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

March 07, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 ↗

March 05, 2024

APGE stock results show that Apogee Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

March 05, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Crude Oil Down 1%; Dave Shares Jump After Q4 Results ↗

March 05, 2024

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 05, 2024

Via Benzinga

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 05, 2024

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.

Via Benzinga

Nasdaq Down 250 Points; ISM Services PMI Falls In February ↗

March 05, 2024

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded down 0.64% to 38,741.00 while the NASDAQ fell 1.64% to 15,942.27. The...

Via Benzinga

Topics Stocks

Why Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday? ↗

March 05, 2024

Apogee Therapeutics unveils promising Phase 1 data for APG777, a lead candidate for atopic dermatitis treatment. Interim results show sustained biomarker inhibition and favorable safety profile. Phase...

Via Benzinga

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday ↗

March 05, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

Via Benzinga

Topics Stocks

Dow Dips Over 100 Points; Target Posts Upbeat Earnings ↗

March 05, 2024

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.33% to 38,861.95 while the NASDAQ...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 05, 2024

Via Benzinga

IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome ↗

March 05, 2024

IPO stock Apogee eyed new highs Tuesday after its developmental inflammation treatment beat trial study objectives.

Via Investor's Business Daily

Topics Initial Public Offering

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

March 05, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of

March 05, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

March 04, 2024

From Apogee Therapeutics, LLC

Via GlobeNewswire

IPO watch 2024: Which new stocks will hit the market?

January 08, 2024

Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies.

Via MarketBeat

Topics Initial Public Offering

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.